HBM HOLDINGS-B (02142): Partner Solstice Oncology completes $225 million Series A financing and officially starts operations.

HBM HOLDINGS-B (02142) announced that its partner company, Solstice Oncology (Solstice), has completed a $225 million Series A financing round and officially commenced operations. This financing round was led by RA Capital Management, with participation from Canaan Partners, Forbion, and other investors. Solstice is a clinical-stage tumor immunotherapy company dedicated to intervening in cancer earlier during the neoadjuvant treatment phase. Solstice is advancing its lead candidate, Prusabumab, a second-generation Fc-enhanced antibody with differentiated properties that targets cytotoxic T lymphocyte-associated protein 4 (CTLA-4). This candidate is currently being developed for two clinical indications, one of which is microsatellite stable (MSS) colorectal cancer, while the other indication has not yet been disclosed. One of its Phase 2 clinical studies is evaluating the efficacy of Prusabumab in combination with Pembrolizumab as a neoadjuvant treatment for MSS clinical stage II-III colorectal cancer. MSS is the most prevalent subtype of colorectal cancer, and to date, this patient population has not benefitted from immunotherapy. The Phase 2 clinical trial is expected to initiate patient enrollment in early Q4 2026, with data anticipated in the second half of 2027.